메뉴 건너뛰기




Volumn 27, Issue 2, 2009, Pages 235-241

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN A;

EID: 58249094490     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.0000     Document Type: Article
Times cited : (216)

References (42)
  • 1
    • 0032820388 scopus 로고    scopus 로고
    • Sarcomatoid renal carcinoma: The final common dedifferentiation pathway of renal epithelial malignancies
    • Delahunt B: Sarcomatoid renal carcinoma: The final common dedifferentiation pathway of renal epithelial malignancies. Pathology 31:185-190, 1999
    • (1999) Pathology , vol.31 , pp. 185-190
    • Delahunt, B.1
  • 2
    • 17444372707 scopus 로고    scopus 로고
    • A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma
    • Lohse CM, Cheville JC: A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 25:433-464, 2005
    • (2005) Clin Lab Med , vol.25 , pp. 433-464
    • Lohse, C.M.1    Cheville, J.C.2
  • 3
    • 0023193247 scopus 로고
    • Sarcomatoid renal cell carcinoma: A treatable entity
    • Sella A, Logothetis CJ, Ro JY, et al: Sarcomatoid renal cell carcinoma: A treatable entity. Cancer 60:1313-1318, 1987
    • (1987) Cancer , vol.60 , pp. 1313-1318
    • Sella, A.1    Logothetis, C.J.2    Ro, J.Y.3
  • 4
    • 33947198698 scopus 로고    scopus 로고
    • Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma
    • Tickoo SK, Alden D, Olgac S, et al: Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol 177:1258-1263, 2007
    • (2007) J Urol , vol.177 , pp. 1258-1263
    • Tickoo, S.K.1    Alden, D.2    Olgac, S.3
  • 5
    • 33847682904 scopus 로고    scopus 로고
    • Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma
    • Kwak C, Park YH, Jeong CW, et al: Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 95:317-323, 2007
    • (2007) J Surg Oncol , vol.95 , pp. 317-323
    • Kwak, C.1    Park, Y.H.2    Jeong, C.W.3
  • 6
    • 0036136548 scopus 로고    scopus 로고
    • Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma
    • Mian BM, Bhadkamkar N, Slaton JW, et al: Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167:65-70, 2002
    • (2002) J Urol , vol.167 , pp. 65-70
    • Mian, B.M.1    Bhadkamkar, N.2    Slaton, J.W.3
  • 7
    • 0023099129 scopus 로고
    • Sarcomatoid renal cell carcinoma: Clinicopathologic - A study of 42 cases
    • Ro JY, Ayala AG, Sella A, et al: Sarcomatoid renal cell carcinoma: Clinicopathologic - A study of 42 cases. Cancer 59:516-526, 1987
    • (1987) Cancer , vol.59 , pp. 516-526
    • Ro, J.Y.1    Ayala, A.G.2    Sella, A.3
  • 8
    • 0033014968 scopus 로고    scopus 로고
    • Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy
    • Cangiano T, Liao J, Naitoh J, et al: Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17:523-528, 1999
    • (1999) J Clin Oncol , vol.17 , pp. 523-528
    • Cangiano, T.1    Liao, J.2    Naitoh, J.3
  • 9
    • 0035116618 scopus 로고    scopus 로고
    • Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases
    • de Peralta-Venturina M, Moch H, Amin M, et al: Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases. Am J Surg Pathol 25:275-284, 2001
    • (2001) Am J Surg Pathol , vol.25 , pp. 275-284
    • de Peralta-Venturina, M.1    Moch, H.2    Amin, M.3
  • 10
    • 0037377944 scopus 로고    scopus 로고
    • Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects
    • Kuroda N, Toi M, Hiroi M, et al: Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 18:551-555, 2003
    • (2003) Histol Histopathol , vol.18 , pp. 551-555
    • Kuroda, N.1    Toi, M.2    Hiroi, M.3
  • 11
    • 58249096408 scopus 로고    scopus 로고
    • The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas
    • abstr 1641
    • Tamboli P, Prieto VG, Bekele BN, et al: The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas. Proc Am Soc Clin Oncol 22:408a, 2003 (abstr 1641)
    • (2003) Proc Am Soc Clin Oncol , vol.22
    • Tamboli, P.1    Prieto, V.G.2    Bekele, B.N.3
  • 12
    • 33748919644 scopus 로고    scopus 로고
    • Biologic significance of fascin expression in clear cell renal cell carcinoma: Systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique
    • Zigeuner R, Droschl N, Tauber V, et al: Biologic significance of fascin expression in clear cell renal cell carcinoma: Systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. Urology 68:518-522, 2006
    • (2006) Urology , vol.68 , pp. 518-522
    • Zigeuner, R.1    Droschl, N.2    Tauber, V.3
  • 13
    • 33845585780 scopus 로고    scopus 로고
    • Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway
    • suppl; abstr 4539, 387s
    • Figlin RA, Seligson D, Wu H, et al: Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Clin Oncol 23:387s, 2005 (suppl; abstr 4539)
    • (2005) J Clin Oncol , vol.23
    • Figlin, R.A.1    Seligson, D.2    Wu, H.3
  • 14
    • 0028898538 scopus 로고
    • Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas
    • Oda H, Nakatsuru Y, Ishikawa T: Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 55:658-662, 1995
    • (1995) Cancer Res , vol.55 , pp. 658-662
    • Oda, H.1    Nakatsuru, Y.2    Ishikawa, T.3
  • 15
    • 1842529797 scopus 로고    scopus 로고
    • Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome
    • Cheville JC, Lohse CM, Zincke H, et al: Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435-441, 2004
    • (2004) Am J Surg Pathol , vol.28 , pp. 435-441
    • Cheville, J.C.1    Lohse, C.M.2    Zincke, H.3
  • 16
    • 0023200226 scopus 로고
    • Sarcomatoid carcinoma of the kidney
    • Bertoni F, Ferri C, Benati A, et al: Sarcomatoid carcinoma of the kidney. J Urol 137:25-28, 1987
    • (1987) J Urol , vol.137 , pp. 25-28
    • Bertoni, F.1    Ferri, C.2    Benati, A.3
  • 17
    • 0028931821 scopus 로고
    • Treatment of sarcomatoid renal cell carcinoma: Is there a role for chemotherapy?
    • Culine S, Bekradda M, Terrier-Lacombe MJ, et al: Treatment of sarcomatoid renal cell carcinoma: Is there a role for chemotherapy? Eur Urol 27:138-141, 1995
    • (1995) Eur Urol , vol.27 , pp. 138-141
    • Culine, S.1    Bekradda, M.2    Terrier-Lacombe, M.J.3
  • 18
    • 0031809054 scopus 로고    scopus 로고
    • Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma
    • Wu J, Caliendo G, Hu XP, et al: Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma. Med Oncol 15:44-49, 1998
    • (1998) Med Oncol , vol.15 , pp. 44-49
    • Wu, J.1    Caliendo, G.2    Hu, X.P.3
  • 19
    • 4243490113 scopus 로고    scopus 로고
    • Phase I Study of Outpatient Interferon-A (IFN), Doxorubicin (DOXO), and Ifosfamide (IFOS) for Patients with Metastatic Sarcomatoid Carcinoma
    • abstr 1371
    • Wood L, Amato R, Daliani D, et al: Phase I Study of Outpatient Interferon-A (IFN), Doxorubicin (DOXO), and Ifosfamide (IFOS) for Patients with Metastatic Sarcomatoid Carcinoma. J Clin Oncol 18:355a, 1999 (abstr 1371)
    • (1999) J Clin Oncol , vol.18
    • Wood, L.1    Amato, R.2    Daliani, D.3
  • 20
    • 0036719229 scopus 로고    scopus 로고
    • Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A phase II study of the Genitourinary Group of the French Federation of Cancer Centers
    • Escudier B, Droz JP, Rolland F, et al: Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol 168:959-961, 2002
    • (2002) J Urol , vol.168 , pp. 959-961
    • Escudier, B.1    Droz, J.P.2    Rolland, F.3
  • 21
    • 4844231761 scopus 로고    scopus 로고
    • Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
    • Nanus DM, Garino A, Milowsky MI, et al: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101:1545-1551, 2004
    • (2004) Cancer , vol.101 , pp. 1545-1551
    • Nanus, D.M.1    Garino, A.2    Milowsky, M.I.3
  • 22
    • 41049109411 scopus 로고    scopus 로고
    • A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma
    • Amato RJ, Khan M: A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. Cancer Chemother Pharmacol 61:1069-1073, 2008
    • (2008) Cancer Chemother Pharmacol , vol.61 , pp. 1069-1073
    • Amato, R.J.1    Khan, M.2
  • 24
    • 0024460781 scopus 로고    scopus 로고
    • Lupera H, Theodore C, Ghosn M, et al: Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer. Urology 34:281-283, 1989
    • Lupera H, Theodore C, Ghosn M, et al: Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer. Urology 34:281-283, 1989
  • 25
    • 0035108057 scopus 로고    scopus 로고
    • Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: Case report and review of the literature
    • Bangalore N, Bhargava P, Hawkins MJ, et al: Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: Case report and review of the literature. Ann Oncol 12:271-274, 2001
    • (2001) Ann Oncol , vol.12 , pp. 271-274
    • Bangalore, N.1    Bhargava, P.2    Hawkins, M.J.3
  • 26
    • 0037998248 scopus 로고    scopus 로고
    • Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma
    • Hoshi S, Satoh M, Ohyama C, et al: Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma. Int J Clin Oncol 8:113-117, 2003
    • (2003) Int J Clin Oncol , vol.8 , pp. 113-117
    • Hoshi, S.1    Satoh, M.2    Ohyama, C.3
  • 27
    • 13444268939 scopus 로고    scopus 로고
    • Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma
    • Rashid MH, Welsh CT, Bissada NK, et al: Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. Am J Clin Oncol 28:107-108, 2005
    • (2005) Am J Clin Oncol , vol.28 , pp. 107-108
    • Rashid, M.H.1    Welsh, C.T.2    Bissada, N.K.3
  • 28
    • 18844386435 scopus 로고    scopus 로고
    • Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
    • Upton MP, Parker RA, Youmans A, et al: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28:488-495, 2005
    • (2005) J Immunother , vol.28 , pp. 488-495
    • Upton, M.P.1    Parker, R.A.2    Youmans, A.3
  • 29
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3
  • 30
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 31
    • 34548315347 scopus 로고    scopus 로고
    • Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
    • suppl; abstr 5023, 240s
    • Bukowski RM, Eisen T, Szczylik C, et al: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol 25:240s, 2007 (suppl; abstr 5023)
    • (2007) J Clin Oncol , vol.25
    • Bukowski, R.M.1    Eisen, T.2    Szczylik, C.3
  • 32
    • 34648873387 scopus 로고    scopus 로고
    • Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis
    • suppl; abstr 5010, 237s
    • Gore ME, Porta C, Oudard S, et al: Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 25:237s, 2007 (suppl; abstr 5010)
    • (2007) J Clin Oncol , vol.25
    • Gore, M.E.1    Porta, C.2    Oudard, S.3
  • 33
    • 34648863567 scopus 로고    scopus 로고
    • The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy
    • suppl; abstr 5011, 237s
    • Knox JJ, Figlin RA, Stadler WM, et al: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oncol 25:237s, 2007 (suppl; abstr 5011)
    • (2007) J Clin Oncol , vol.25
    • Knox, J.J.1    Figlin, R.A.2    Stadler, W.M.3
  • 34
    • 33744954585 scopus 로고    scopus 로고
    • Sunitinib in patients with metastatic renal cell carcinoma
    • Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006
    • (2006) JAMA , vol.295 , pp. 2516-2524
    • Motzer, R.J.1    Rini, B.I.2    Bukowski, R.M.3
  • 35
    • 57449097893 scopus 로고    scopus 로고
    • Sunitinib and bevacizumab in advanced solid tumors: A phase I trial
    • suppl; abstr 3530, 160s
    • Cooney MM, Garcia JA, Elson P, et al: Sunitinib and bevacizumab in advanced solid tumors: A phase I trial. J Clin Oncol 26:160s, 2008 (suppl; abstr 3530)
    • (2008) J Clin Oncol , vol.26
    • Cooney, M.M.1    Garcia, J.A.2    Elson, P.3
  • 36
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 37
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 38
    • 33645763970 scopus 로고    scopus 로고
    • WHO classification of the renal tumors of the adults
    • Lopez-Beltran A, Scarpelli M, Montironi R, et al: 2004 WHO classification of the renal tumors of the adults. Eur Urol 49:798-805, 2006
    • (2004) Eur Urol , vol.49 , pp. 798-805
    • Lopez-Beltran, A.1    Scarpelli, M.2    Montironi, R.3
  • 39
    • 0036138580 scopus 로고    scopus 로고
    • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    • Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 289-296
    • Motzer, R.J.1    Bacik, J.2    Murphy, B.A.3
  • 40
    • 34547108341 scopus 로고    scopus 로고
    • Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    • Choueiri TK, Garcia JA, Elson P, et al: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543-550, 2007
    • (2007) Cancer , vol.110 , pp. 543-550
    • Choueiri, T.K.1    Garcia, J.A.2    Elson, P.3
  • 41
    • 58249124806 scopus 로고    scopus 로고
    • A phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors
    • Presented at, San Francisco, CA, February 14-16
    • Michaelson M, Schwarzberg A, Ryan D, et al: A phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. Presented at ASCO Genitourinary Cancers Symposium, San Francisco, CA, February 14-16, 2008
    • (2008) ASCO Genitourinary Cancers Symposium
    • Michaelson, M.1    Schwarzberg, A.2    Ryan, D.3
  • 42
    • 56249108812 scopus 로고    scopus 로고
    • Sorafenib is superior to combination therapy with gemcitabine plus doxorubicin for patients with sarcomatoid renal cell carcinoma
    • Presented at, San Francisco, CA, February 14-16
    • Staehler M, Schöppler G, Haseke N, et al: Sorafenib is superior to combination therapy with gemcitabine plus doxorubicin for patients with sarcomatoid renal cell carcinoma. Presented at ASCO Genitourinary Cancers Symposium, San Francisco, CA, February 14-16, 2008
    • (2008) ASCO Genitourinary Cancers Symposium
    • Staehler, M.1    Schöppler, G.2    Haseke, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.